Washington, DC - Following a public comment period, the Federal Trade Commission has approved a final order settling charges that the $8 billion merger  between Endo International plc and Par Pharmaceuticals, Inc. would likely be anticompetitive.

Under the order, first announced in September 2015, the companies are required to sell Endo’s U.S. rights and assets for generic glycopyrrolate tablets, which are used with other drugs to treat certain types of ulcers, and generic methimazole tablets, which are used to treat the body’s production of excess thyroid hormone to Rising Pharmaceuticals.

 The Commission vote approving the final order was 4-0. (FTC File No. 151 0137; the staff contact is Stephanie C. Bovee, Bureau of Competition, 202-326-2083)